Alumis Inc Reports Q3 2026 Earnings: GAAP EPS of -0.78 and Revenue of $1. ...
Clinical-Stage Biotech Reports No Product Revenue, Wider-Than-Expected Per-Share Loss, and Advances Toward a Fourth-Quarter 2026 Psoriasis Filing Related Stocks: ALMS ,
Clinical-Stage Biotech Reports No Product Revenue, Wider-Than-Expected Per-Share Loss, and Advances Toward a Fourth-Quarter 2026 Psoriasis Filing Related Stocks: ALMS ,